Healthcare Industry News: sanofi-aventis
News Release - November 19, 2013
Antares Pharma Appoints David H. Bergstrom Ph.D. as Senior Vice President Pharmaceutical DevelopmentEWING, N.J.--(Healthcare Sales & Marketing Network)--Antares Pharma, Inc. (ATRS) today announced the appointment of David H. Bergstrom Ph.D. to the position of Senior Vice President of Pharmaceutical Development. Dr. Bergstrom is an experienced, operations focused executive with a leadership background in large, small and semi-virtual pharmaceutical companies as well as in the contract product development and manufacturing industry. He received his Ph.D. in Pharmaceutics from the University of Utah, Salt Lake City, Utah.
Dr. Bergstrom comes to Antares Pharma from Advantar Laboratories where he was the Executive Vice President and Chief Operating Officer. Prior to joining Advantar, he was the Senior Vice President and COO for NovaDel Pharmaceuticals. Dr. Bergstrom previously served as Senior Vice President and General Manager of the Pharmaceutical Development business of Cardinal Health, Inc. Prior to Cardinal Health, Dr. Bergstrom served as Vice President of Pharmaceutical and Chemical Development at Guilford Pharmaceuticals and also served in senior positions in preclinical development and pharmaceutical and analytical development at Hoechst-Roussel Pharmaceuticals, Inc., predecessor companies of sanofi-aventis Pharmaceuticals, Inc. Prior to that, Dr. Bergstrom worked in pharmaceutical development at CIBA-Geigy Pharmaceuticals, Inc.
“We are very pleased to welcome Dr. Bergstrom to the Antares team,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “David has a proven track record as a leader of product development teams and has worked on multiple FDA approved products including 505B2 drug/device combination programs. His broad product development expertise will help drive our pipeline initiative and insure that we continue to execute our programs aggressively and expedite future product launches such as Quick Shot™ testosterone and QS M.”
About Antares Pharma
Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company has received marketing approval from the U.S. Food and Drug Administration for OTREXUP™ (methotrexate) injection for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Antares Pharma is also developing VIBEX® QS T for testosterone replacement therapy. The Company's technology platforms include VIBEX® disposable Medi-Jet, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® [somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX® epinephrine and several other products. Antares Pharma’s partnership with Ferring includes Zomacton® hGH (somatropin) injection. In the U.S. Antares has received FDA approval for Gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted Medi-Jet and pen injector systems. The Company’s corporate office and Product Development and Commercial Groups are located in Ewing, New Jersey.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are indicated by the words “may,” “will,” “plans,” “intends,” “believes,” “expects,” “anticipates,” “potential,” “could,” “would,” “should,” and similar expressions. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, among others, changes in revenue growth and difficulties or delays in the commercial launch of OTREXUP™, market acceptance by physicians and patients of new products, delays in product development and changes or delays in the regulatory process for existing or new product candidates. In addition, the Quick Shot™ testosterone and the QS M products referred to in this press release have not yet been approved by the FDA, and the commercialization of Quick Shot testosterone and QS M are dependent on the FDA approving these products. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.
Source: Antares Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.